Agent containing 4-phenylbutyrate, for preventing or treating presbyopia

Patent metadata

Field	Value
Publication number	US-2022062209-A1
Application number	US-201917414286-A
Country	US
Kind code	A1
Filing date	Dec 17, 2019
Priority date	Dec 18, 2018
Publication date	Mar 3, 2022
Grant date	—

Abstract

The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof.

First claim

1 . (canceled)

2 . (canceled)

3 . (canceled)

4 . (canceled)

5 . (canceled)

6 . (canceled)

7 . (canceled)

8 . (canceled)

9 . (canceled)

10 . (canceled)

11 . A method for treating or preventing presbyopia, comprising administering to a subject in need thereof an effective amount of 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof.

12 . The method according to claim 11 , wherein the 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof, is administered ophthalmically.

13 . The method according to claim 11 , wherein the 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof, is administered as an eye drop or an eye ointment.

14 . The method according to claim 13 , wherein the amount of 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof, comprised in the eye drop or the eye ointment is 0.00001 to 10% (w/v).

15 . The method according to claim 11 , wherein the 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof, is 4-phenylbutyric acid or a sodium salt thereof.

16 . The method according to claim 13 , wherein the eye drop or the eye ointment comprises water, and an additive selected from ethyl pyruvate, sodium dihydrogenphosphate monohydrate, disodium hydrogenphosphate, hydroxypropyl methylcellulose, NaCl, or a mixture thereof.

17 . A method for treating or preventing an eye disease accompanied by a decrease in lens elasticity, comprising administering to a subject in need thereof an effective amount of 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof.

18 . A method for treating or preventing an eye disease accompanied by a decrease in accommodative function of the eye, comprising administering to a subject in need thereof an effective amount of 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof.

Assignees

• Santen Pharmaceutical Co Ltd

Inventors

• Kato Masatomo
• Oda Tomoko
• Nozaki Kensuke

Classifications

• A61K31/192 Primary

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• A61P27/10

  for accommodation disorders, e.g. myopia · CPC title

• A61K47/14

  Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title

• A61K9/06

  Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title